Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective and Head-to-head Comparison of [68Ga] Ga-DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies: NET-COMPARE Study

NCT07621146 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT07621146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07621146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective and Head-to-head Comparison of [68Ga] Ga-DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies: NET-COMPARE Study
Lead sponsor
British Columbia Cancer Agency
Phase
Observational
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
March 31, 2028
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

medullary thyroid carcinoma, neuroendocrine tumors, net, pheochromocytoma/paraganglioma, sstr-expressing tumors